{"nctId":"NCT00055497","briefTitle":"Remission in Subjects With Crohn's Disease, 1 Year Phase","startDateStruct":{"date":"2002-08"},"conditions":["Crohn's Disease"],"count":276,"armGroups":[{"label":"Double-blind (DB) adalimumab placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Double-blind (DB) adalimumab placebo"]},{"label":"Double-blind adalimumab 40 mg every other week (eow)","type":"EXPERIMENTAL","interventionNames":["Biological: DB adalimumab 40 mg eow"]},{"label":"Double-blind adalimumab 40 mg every week (ew)","type":"EXPERIMENTAL","interventionNames":["Biological: DB adalimumab 40 mg ew"]},{"label":"Open-label adalimumab 40 mg","type":"EXPERIMENTAL","interventionNames":["Biological: OL adalimumab 40 mg"]}],"interventions":[{"name":"Double-blind (DB) adalimumab placebo","otherNames":["Humira速"]},{"name":"DB adalimumab 40 mg eow","otherNames":["Humira速"]},{"name":"DB adalimumab 40 mg ew","otherNames":["Humira速"]},{"name":"OL adalimumab 40 mg","otherNames":["Humira速"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Patient must have successfully completed the induction study NCT00055523\n* Diagnosis of Crohn's disease\n* Willing and able to give informed consent\n\nExclusion:\n\n* Diagnosis of ulcerative colitis\n* Pregnancy or breastfeeding\n* Previous use of infliximab or other anti-TNF antagonists\n* Previous history of active tuberculosis or listeria infection\n* Previous history of cancer other than successfully treated skin cancer","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants Achieving Clinical Remission at Week 24 - NRI","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OL Participants Achieving Clinical Remission at Week 56 - NRI","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Randomized Participants Achieving Clinical Remission at Week 56 - Non-Responder Imputation (NRI)","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Randomized Participants Achieving Clinical Remission at Week 56 - Last Observation Carried Forward (LOCF)","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Clinical Response 100 (CR-100) - NRI","description":"A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Clinical Response 70 (CR-70)- NRI","description":"A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Clinical Remission at Week 24 - LOCF","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OL Participants Achieving Clinical Remission at Week 56 - LOCF","description":"Clinical remission is defined as CDAI score \\<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving CR-100 - LOCF","description":"A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving CR-70 - LOCF","description":"A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \\>/= 0 and without upper limit. The range of scores during Study NCT00055497 and the lead-in study (NCT00055523) was 0 to 633. A lower score indicates less severe Crohn's disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"147","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores - LOCF","description":"IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue \"all of the time\") and 7=good quality on the item (e.g., feeling of fatigue \"none of the time\"). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"43.4","spread":null},{"groupId":"OG002","value":"51.9","spread":null},{"groupId":"OG003","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"45.2","spread":null},{"groupId":"OG003","value":"36.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Nasopharyngitis","Crohn's disease aggravated","Headache","Arthralgia","Nausea"]}}}